SCHEMBL2424987

SCHEMBL2424987

O=S(=O)(Nc1nc2ccccc2nc1OCc1cccnc1)c1ccccc1-c1cccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 4/20 0.54
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 3/20 0.41
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
SCN9A Q15858 1/20 0.40
EDNRA P25101 1/20 0.40
MEN1 O00255 4/20 0.39
MAPK1 P28482 1/20 0.38
POLB P06746 1/20 0.38
NAMPT P43490 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2427956 0.92 CCR4 (0.57) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038896 0.83 CCR4 (0.56) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL2424076 0.83 CCR4 (0.77) CCR4
SCHEMBL3293600 0.81 CCR4 (0.64) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL6039136 0.81 KDM4E (0.63) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL12281897 0.79 CCR4 (0.77) CCR4KMT2ASCN9AEDNRA
SCHEMBL6038408 0.77 MEN1 (0.62) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038910 0.77 KDM4E (0.56) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL6039075 0.77 KDM4E (0.53) CCR4KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038804 0.77 MEN1 (0.66) CCR4KMT2AKDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYOWA KIRIN CO., LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYNU, KMO, IDO1 CCR4 3284/4885KMT2A 464/4885KDM4E 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.